Efficacy and safety analysis of recombinant human endostatin combined with EC-T sequential neoadjuvant chemotherapy be-fore radical resection of locally advanced breast cancer in elderly patients
Objective To analyze the efficacy and safety of recombinant human endostatin combined with EC-T se-quential neoadjuvant chemotherapy before radical resection of locally advanced breast cancer(LABC)in elderly patients,and provide methods for clinical diagnosis and treatment.Methods A total of 80 elderly patients with LABC treated in Traditional Chinese Medicine Hospital of Guangde City from January 2015 to September 2022 were retrospectively selected.They were di-vided into observation group(40 cases)and control group(40 cases)according to different treatment methods.The control group was treated with EC-T sequential neoadjuvant chemotherapy before radical treatment,and the observation group was trea-ted with recombinant human endostatin on the basis of the same treatment as the control group.The clinical efficacy,serum tumor marker level and adverse reactions were compared between the two groups.Results After treatment,the treatment ef-fective rate and disease control rate of the observation group were higher than those of the control group(75.00％vs 52.50％,92.50％vs75.00％,P＜0.05).After treatment,the levels of serum CA125 and CEA of both groups were lower than those of the same group before treatment,and the observation group was lower than the control group(P＜0.05).The patients were followed up for 12 months after treatment,and the survival rate of the observation group was higher than that of the control group(92.50％vs 72.50％,P＜0.05).There were no significant differences in the incidence of liver function impairment,leukopenia,cardiac function impairment,thrombocytopenia,skin reaction and gastrointestinal reaction between the two groups(P＞0.05).Conclusion The combination of recombinant human endostatin and EC-T sequential neoadjuvant chemotherapy before radical resection of locally advanced breast cancer can improve the clinical efficacy in elderly patients,reduce the levels of serum tumor markers,but not increase the adverse reactions of patients.
elderlyadvanced breast cancerrecombinant human endostatinEC-T sequential chemotherapyclinical efficacy
国家科技期刊平台
NSTL
万方数据
